Too narrow a focus on regulatory compliance may prevent organizations from embracing-and profiting from-quality and operational excellence.
Regulators and pharmaceutical manufacturers are debating the best way to measure quality. Discussions center on management and corporate cultures and how they impact operational excellence and customer-focused quality. Observers see the need for more proactive pharmaceutical company managers who actively support and invest in quality efforts and employee training.
Read this article in Pharmaceutical Technology’s December 2019 Regulatory Sourcebook.
Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 6–10
When referring to this article, please cite it as A. Shanley, “Moving from Compliance to Quality," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.